Martingale Asset Management L P Acquires 12,607 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Martingale Asset Management L P has increased its stake in Supernus Pharmaceuticals by 28.3%, now owning 57,199 shares valued at approximately $1.87 million.
• Wall Street analysts have shown confidence in Supernus Pharmaceuticals, with Zacks Research upgrading its rating to "hold" and Cantor Fitzgerald raising the target price from $42.00 to $46.00.
• Despite some insider selling, Supernus Pharmaceuticals' stock rose by 3.6%, reaching a recent price of $44.88 with a market cap of $2.52 billion.

Martingale Asset Management L P grew its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 28.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 57,199 shares of the specialty pharmaceutical company's stock after buying an additional 12,607 shares during the period. Martingale Asset Management L P owned 0.10% of Supernus Pharmaceuticals worth $1,873,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. LPL Financial LLC boosted its stake in Supernus Pharmaceuticals by 18.9% during the fourth quarter. LPL Financial LLC now owns 12,741 shares of the specialty pharmaceutical company's stock worth $461,000 after acquiring an additional 2,029 shares in the last quarter. Wells Fargo & Company MN increased its stake in shares of Supernus Pharmaceuticals by 14.4% during the fourth quarter. Wells Fargo & Company MN now owns 63,237 shares of the specialty pharmaceutical company's stock valued at $2,287,000 after purchasing an additional 7,961 shares in the last quarter. Envestnet Asset Management Inc. lifted its holdings in shares of Supernus Pharmaceuticals by 6.2% during the fourth quarter. Envestnet Asset Management Inc. now owns 59,970 shares of the specialty pharmaceutical company's stock valued at $2,169,000 after purchasing an additional 3,495 shares during the last quarter. Bank of Montreal Can boosted its position in shares of Supernus Pharmaceuticals by 6.6% in the 4th quarter. Bank of Montreal Can now owns 7,595 shares of the specialty pharmaceutical company's stock worth $275,000 after purchasing an additional 473 shares in the last quarter. Finally, Barclays PLC boosted its position in shares of Supernus Pharmaceuticals by 12.9% in the 4th quarter. Barclays PLC now owns 122,849 shares of the specialty pharmaceutical company's stock worth $4,442,000 after purchasing an additional 14,061 shares in the last quarter.

Supernus Pharmaceuticals Trading Up 0.6%

NASDAQ:SUPN traded up $0.27 during mid-day trading on Thursday, reaching $45.34. The company's stock had a trading volume of 173,987 shares, compared to its average volume of 638,408. The stock has a market cap of $2.54 billion, a P/E ratio of 39.36 and a beta of 0.74. The firm's fifty day moving average price is $36.13 and its two-hundred day moving average price is $33.85. Supernus Pharmaceuticals, Inc. has a 12-month low of $29.16 and a 12-month high of $45.60.

Wall Street Analysts Forecast Growth

SUPN has been the subject of a number of analyst reports. Wall Street Zen raised Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Zacks Research raised Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 19th. Finally, Cantor Fitzgerald lifted their price target on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 6th. Two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $41.00.

Insider Activity at Supernus Pharmaceuticals

In other news, Director Frederick M. Hudson sold 7,457 shares of the stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $42.26, for a total transaction of $315,132.82. Following the transaction, the director directly owned 46,307 shares of the company's stock, valued at $1,956,933.82. This represents a 13.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Bethany Sensenig sold 5,369 shares of the business's stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $42.25, for a total value of $226,840.25. The disclosure for this sale can be found here. Insiders have sold 179,606 shares of company stock valued at $7,617,005 over the last quarter. 8.80% of the stock is owned by company insiders.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.